$3.14 Billion is the total value of EcoR1 Capital, LLC's 76 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| APLS | New | APELLIS PHARMACEUTICALS INC | $190,722,000 | – | 4,033,882 | +100.0% | 6.08% | – |
| CRSP | New | CRISPR THERAPEUTICS AGnamen akt | $81,652,000 | – | 1,077,483 | +100.0% | 2.60% | – |
| ACAD | New | ACADIA PHARMACEUTICALS INC | $71,434,000 | – | 3,060,593 | +100.0% | 2.28% | – |
| New | 2SEVENTY BIO ORD | $49,134,000 | – | 1,917,063 | +100.0% | 1.57% | – | |
| AVIR | New | ATEA PHARMACEUTICALS INC | $48,063,000 | – | 5,376,134 | +100.0% | 1.53% | – |
| SAGE | New | SAGE THERAPEUTICS INC | $40,015,000 | – | 940,636 | +100.0% | 1.28% | – |
| New | PARDES BIOSCIENCES ORD | $26,145,000 | – | 1,597,139 | +100.0% | 0.83% | – | |
| New | VENTYX BIOSCIENCES ORD | $25,818,000 | – | 1,300,000 | +100.0% | 0.82% | – | |
| CRNX | New | CRINETICS PHARMACEUTICALS IN | $16,767,000 | – | 590,169 | +100.0% | 0.53% | – |
| ALNY | New | ALNYLAM PHARMACEUTICALS INC | $16,644,000 | – | 98,146 | +100.0% | 0.53% | – |
| HALO | New | HALOZYME THERAPEUTICS INC | $15,762,000 | – | 392,000 | +100.0% | 0.50% | – |
| LEGN | New | LEGEND BIOTECH CORPsponsored ads | $14,337,000 | – | 307,594 | +100.0% | 0.46% | – |
| ARVN | New | ARVINAS INC | $10,703,000 | – | 130,300 | +100.0% | 0.34% | – |
| GRPH | New | GRAPHITE BIO INC | $8,563,000 | – | 688,900 | +100.0% | 0.27% | – |
| AMTI | New | APPLIED MOLECULAR TRANS INC | $5,592,000 | – | 400,000 | +100.0% | 0.18% | – |
| GRTS | New | GRITSTONE BIO INCcall | $3,948,000 | – | 307,000 | +100.0% | 0.13% | – |
| ADVM | New | ADVERUM BIOTECHNOLOGIES INC | $1,842,000 | – | 1,046,700 | +100.0% | 0.06% | – |
| ALGS | New | ALIGOS THERAPEUTICS INC | $1,081,000 | – | 91,044 | +100.0% | 0.03% | – |
| VTVT | New | VTV THERAPEUTICS INCcl a | $830,000 | – | 834,333 | +100.0% | 0.03% | – |
| GLUE | New | MONTE ROSA THERAPEUTICS INC | $768,000 | – | 37,593 | +100.0% | 0.02% | – |
| PCVX | New | VAXCYTE INC | $495,000 | – | 20,800 | +100.0% | 0.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| KURA ONCOLOGY ORD | 32 | Q3 2023 | 10.5% |
| XENCOR ORD | 25 | Q3 2023 | 12.6% |
| ASSEMBLY BIOSCIENCES ORD | 23 | Q3 2020 | 19.0% |
| FIBROGEN ORD | 22 | Q1 2020 | 12.4% |
| PROTHENA ORD | 20 | Q3 2023 | 28.0% |
| IRONWOOD PHARMA CL A ORD | 20 | Q1 2020 | 13.9% |
| GALAPAGOS NV SPON ADR | 19 | Q3 2023 | 12.0% |
| MORPHIC HOLDING ORD | 18 | Q3 2023 | 8.5% |
| ARCUS BIOSCIENCES ORD | 17 | Q1 2022 | 7.1% |
| ANAPTYSBIO INC | 16 | Q3 2023 | 8.3% |
View EcoR1 Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Mersana Therapeutics, Inc. | July 27, 2023 | 19,364,688 | 16.9% |
| TScan Therapeutics, Inc. | June 05, 2023 | 5,000,000 | 11.7% |
| 2seventy bio, Inc. | February 14, 2023 | 1,143,494 | 3.0% |
| Avidity Biosciences, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Surface Oncology, Inc. | February 13, 2023 | 3,924,713 | 6.5% |
| Akouos, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Alector, Inc. | February 10, 2023 | 4,056,548 | 4.9% |
| Arcus Biosciences, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Gritstone bio, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Ovid Therapeutics Inc. | February 10, 2023 | 6,117,400 | 8.7% |
View EcoR1 Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-03 |
| SC 13G/A | 2024-04-08 |
| 3 | 2024-03-26 |
| SC 13G/A | 2024-03-26 |
| SC 13G | 2024-03-11 |
| SC 13D | 2024-02-22 |
| SC 13G | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View EcoR1 Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.